Jaume Pons, PhD

Dr. Pons is co-founder of ALX Oncology, a publicly traded immuno-oncology company that he led as CEO from inception in April 2015 to September 2023, including IPO in 2020. Since September 2023 Dr. Pons serves as President and CSO focusing in the future portfolio and technology of the company. He is also co-founder and BOD member of Tallac Therapeutics, a venBio funded private company, that focuses on treatment of cancer using CPG-antibody conjugates.

Previously, as Senior Vice-President at Pfizer, he was Chief Scientific Officer and site head of Rinat (Pfizer) from 2007 to 2015, where he was responsible for portfolio delivery from idea to human proof of concept. During his tenure at Pfizer, Dr. Pons also served as Chief Technology Officer for Biotherapeutics, focusing on the evaluation and licensing of new platform technologies, member of Pfizer’s World R&D Leadership Team and member of the Portfolio Strategy Investment committee, the governance body that evaluates Pfizer’s clinical projects and guards the gateway to Phase 3 investment.